Aurobindo Pharma Announces Share Buyback Programme at ₹1,475 Per Share

Aurobindo Pharma Announces ₹800 Crore Share Buyback

Aurobindo Pharma, a leading Indian pharmaceutical company, has announced a share buyback program worth up to ₹800 crore. The company's board of directors made this decision at a meeting held on Monday, 6 April 2026.

Under the share buyback program, the company will purchase up to 54,23,728 fully paid-up equity shares of the company at a price of ₹1,475 per share. This represents a 10% premium over the current market price of Aurobindo Pharma shares, which is oscillating around ₹1,335 apiece on the National Stock Exchange (NSE).

The share buyback offer will be available to all investors who held Aurobindo Pharma shares on 17 April 2026, which has been declared as the record date for the share buyback. The buyback plan will be executed through a tender process.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The company has informed the Indian exchanges about the share buyback move, stating that the board of directors has approved the buyback of up to 0.93% of the total number of equity shares in the paid-up equity share capital of the company. The buyback size does not include transaction costs such as brokerage fees, filing fees, and other expenses.

The share buyback is proposed to be made from all equity shareholders, including promoters and members of the promoter group, who hold shares as of the record date on a proportionate basis through the "tender offer" route.